VLA — Valneva SE Share News
0.000.00%
Last trade - 00:00- €440.83m
- €529.53m
- €174.66m
Valneva rises on vaccines distribution deal in Germany
Brief: Valneva, CSL Seqirus Enter Exclusive Agreement For Vaccine Distribution In Germany
Brief: UK's MHRA Says IXCHIQ Vaccine Will Be Available On The UK Market From June 18
UK's MHRA suspends Valneva's chikungunya vaccine for elderly
Valneva rises on positive mid-stage study data of chikungunya vaccine in children
US CDC accepts recommendations for chikungunya vaccines (updated)
US CDC approves recommendations for chikungunya vaccines
Corrected: BUZZ-Valneva falls as FDA and CDC recommend a pause in use of its chikungunya vaccine for elderly patients
Brief: FDA And CDC Recommend Pause In Use Of Valneva's Chikungunya Vaccine In Elderly
Brief: Valneva Continues To See Positive Risk-Benefit In Majority Of People With Potential Exposure To Disease
Brief: EMA Starts Review Of Ixchiq Following Reports Of Serious Adverse Events In Elderly People
Europe reviews Valneva's chikungunya vaccine after reports of serious side effects (updated)
Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people
Valneva rises after 'dynamic and satisfactory' Q1 results
French and Benelux stocks-Factors to watch
Brief: Valneva Q1 Revenue EUR 49.2 Million
Kennedy aide and vaccine critic questions recent expert recommendations
Kennedy aide and vaccine critic questions recent expert recommendations
Valneva at bottom of SBF120 index after France suspends chikugunya vaccine for elderly